# OnCo record paper-wu-alina-adjuvant-alectinib-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-wu-alina-adjuvant-alectinib-nejm-2024" ;
  schema:name "Alectinib in resected ALK-positive non-small-cell lung cancer"@en ;
  schema:description "After surgery for ALK-positive lung cancer, two years of alectinib kept 93.8 percent of patients disease-free at two years against 63.0 percent on chemotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2310532>, <https://pubmed.ncbi.nlm.nih.gov/38598794/>, <https://clinicaltrials.gov/study/NCT03456076> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2310532> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Wu YL, Dziadziuszko R, Ahn JS, et al." ;
  onco:related <https://onco.cc/key-papers/paper-adaura-nejm-2020/>, <https://onco.cc/key-papers/paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008/>, <https://onco.cc/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/surgery/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/mrd/> ;
  onco:trials <https://onco.cc/trials/alina/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .